CTLA4 and metastatic melanoma: The recent combined immune checkpoint (ICI) inhibition therapy with Ipilimumab (a CTLA-4 blocking agent) and Nivolumab (a PD-1 blocking agent) demonstrated better anticancer outcomes in advanced or metastatic melanoma compared to monotherapy regimen (1).